We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Sunflower Protein May Help Block Tumor Spread in Prostate Cancer

By Biotechdaily staff writers
Posted on 27 May 2008
A mini-protein found in sunflower seeds could be the key to stopping tumors spreading in prostate cancer patients, according to Australian researchers. More...


Dr. Jonathan Harris, a senior lecturer in Queensland University of Technology's (QUIT; Brisbane, Australia) Faculty of Science, and Ph.D. student Joakim Swedberg, from both the University's Institute of Health and from Biomedical Innovation, are working on the naturally occurring molecule.

"We are interested in this miniprotein as a potential treatment of prostate cancer, in particular for those patients who relapse,” said Dr Harris. "We are interested in this miniprotein as a potential treatment of prostate cancer, in particular for those patients who relapse. The best thing to do in those cases is block the disease spreading to other organs, particularly the spine, which is very debilitating; it is not the prostate tumor that kills you, it is when the cancer cells escape from the prostate so we want to prevent that.”

Another QUT researcher, Prof. Judith Clements, had previously demonstrated that the action of enzymes called proteases was a critical process in metastasis, and Dr. Harris reported that the sunflower mini-protein, known as the protease inhibitor, was able to block these enzymes in test tube-based assays.

"However, it also inhibits a whole range of proteases, some of which control important processes in the body, so we have re-engineered the molecule so it should just block the proteases produced in prostate cancer and hence stop tumor spreading, whilst leaving other processes intact,” Dr. Harris remarked.

Dr. Harris and his team will perform tests on the re-engineered inhibitor in animals over the next months. "It feels like we have been covered in a shower of gold at the moment, it is very exciting for us because we are a small team but we have been working very hard on this for a long time,” he said. "We are extremely happy because now we can carry out trials in mouse-models of prostate cancer and if we have positive results, we could get a pharmaceutical industry partner interested in the work. "Currently bluebox, QUT's commercialization company, is helping us towards that goal. The dream end-product is having a drug which could be produced in sunflower seeds and given as a simple dietary supplement for people with prostate cancer.”


Related Links:
Queensland University of Technology

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.